A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma

Archives of Ophthalmology

Volumn 122, Issue 7, 2004, Pages 957-965

  Alm, Albert ^a   Schoenfelder, John ^b   McDermott, Jacquie ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b MedPharm Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; ANTIHYPERTENSIVE AGENT; EYE DROPS; PROSTAGLANDIN F;

ADULT; AGED; ARTICLE; BLEPHARITIS; BRONCHITIS; CATARACT; CLINICAL TRIAL; CONJUNCTIVITIS; CORNEA DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; EXFOLIATION SYNDROME; EYE COLOR; EYE IRRITATION; EYE MALFORMATION; EYE PAIN; EYE PHOTOGRAPHY; FEMALE; FLU LIKE SYNDROME; GLAUCOMA; HEADACHE; HUMAN; HYPEREMIA; HYPERTENSION; HYPERTRICHOSIS; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; IRIS; IRIS PIGMENTATION; LACRIMATION; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OPTIC NERVE ATROPHY; OPTICAL RESOLUTION; PIGMENT DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFRACTION ERROR; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VISUAL DISORDER; VISUAL FIELD DEFECT; ADJUVANT CHEMOTHERAPY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG SCREENING; LONGITUDINAL STUDY; MIDDLE AGED; OPEN ANGLE GLAUCOMA; PATHOPHYSIOLOGY; SAFETY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHEMOTHERAPY, ADJUVANT; DRUG EVALUATION; EXFOLIATION SYNDROME; EYE COLOR; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; IRIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PIGMENTATION DISORDERS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; SAFETY;

EID: 3342959178     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.7.957     Document Type: Article

References (39)

1. Alm A, Stjernschantz J, for the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology. 1995;102:1743-1752.
2. Camras CB, for the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 1996;103:138-147.
3. Watson P, Stjernschantz J, for the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103:126-137.
4. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12-week study. Arch Ophthalmol. 1996;114:929-932.
5. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function. Surv Ophthalmol. 1997;41 (suppl 2):S69-S75.
6. 2α-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989;48:707-716.
7. Weinreb RN, Lindsey JD. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci. 2002;43:716-722.
8. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle: a study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.
9. 2α treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol. 1999;117:794-801.
10. Alm A, Widengård I. Latanoprost: experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 2000;78:71-76.
11. Costagliola C, Del Prete A, Verolino M, et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by β-blockers twice daily: a 3-year follow-up: experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol. 2002;240:379-386.
12. Watson PG, for the Latanoprost Study Group. Latanoprost. Two years' experience of its use in the United Kingdom. Ophthalmology. 1998;105:82-87.
13. Alm A, Widengård I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol. 1995;79:12-16.
14. 2α, analogue and timolol in patients with elevated intraocular pressure. Br J Ophthalmol. 1994;78:899-902.
15. Widengård I, Mäepea O, Alm A. Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability. Br J Ophthalmol. 1998;82:404-406.
16. Friström B, Nilsson SE. Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine: a study on patients with elevated intraocular pressure. Arch Ophthalmol. 1993;111:662-665.
17. O'Donoghue EP, for the UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3-month, randomised study. Br J Ophthalmol. 2000;84:579-582.
18. Wistrand PJ, Stjernschantz J, Olsson K. The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color. Surv Ophthalmol. 1997;41(suppl 2):S129-S138.
19. Selen G, Stjernschantz J, Resul B. Prostaglandin-induced iridial pigmentation in primates. Surv Ophthalmol. 1997;41(suppl 2):S125-S128.
20. Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109:998-1008.
21. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472-484.
22. Sherwood M, Brandt J, for the Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(suppl 4):S361-S368.
23. Yamamoto T, Kitazawa Y. Iris-color change developed after topical isopropyl unoprostone treatment. J Glaucoma. 1997;6:430-432.
24. Grierson I, Cracknell KP, Pfeiffer N. The iris after prostanoid treatment. Curr Opin Ophthalmol. 2001;12:112-118.
25. Chiba T, Kashiwagi K, Kogure S, et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients. J Glaucoma. 2001;10:406-410.
26. Drago F, Marino A, La Manna C. α-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro. Exp Eye Res. 1999;68:85-90.
27. Dutkiewicz R, Albert DM, Levin LA. Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines. Exp Eye Res. 2000;70:563-569.
28. Prota G, Vincensi MR, Napolitano A, Selen G, Stjernschantz J. Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys. Pigment Cell Res. 2000;13:147-150.
29. Stjernschantz J, Ocklind A, Wentzel P, Lake S, Hu D-N. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes. Acta Ophthalmol Scand. 2000;78:6186-6122.
30. 2α, and latanoprost on cultured human iridal melanocytes. Exp Eye Res. 2000;70:113-120.
31. Pfeiffer N, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Böhres A, Appleton P. Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study. Arch Ophthalmol. 2001;119:191-196.
32. Tsai JC, Sivak-Callcott JA, Haik BG, Zhang J, McLean IW. Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologic report. J Glaucoma. 2001;10:411-413.
33. Farrar SM, Shields MB. Current concepts in pigmentary glaucoma. Surv Ophthalmol. 1993;37:233-252.
34. Grierson I, Pfeiffer N, Cracknell KP, Appleton P. Histology and fine structure of the iris and outflow system following latanoprost therapy. Surv Ophthalmol. 2002;47(suppl 1):S176-S184.
35. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand. 1999;77:668-672.
36. Fechtner RD, Khouri AS, Zimmerman TJ, et al. Anterior uveitis associated with latanoprost. Am J Ophthalmol. 1998;126:37-41.
37. Gaddie IB, Bennett DW. Cystoid macula edema associated with the use of latanoprost. J Am Optom Assoc. 1998;69:122-128.
38. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use: experience and incidence in a retrospective review of 94 patients. Ophthalmology. 1998;105:263-268.
39. Furuichi M, Chiba T, Abe K, et al. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma. 2001;10:233-236.